Education
About Us
Working with TipRanks
Follow Us
RegenXBio (RGNX)
NASDAQ:RGNX
RGNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.04 - $15.36
Previous CloseN/A
Volume155.59K
Average Volume (3M)1.25M
Market Cap
$492.07M
Enterprise Value$427.77M
Total Cash (Recent Filing)$267.87M
Total Debt (Recent Filing)$79.85M
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Jul 30, 2025EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding50,160,350
10 Day Avg. Volume1,405,330
30 Day Avg. Volume1,245,703
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-5.50
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue1.03
Enterprise Value/Gross Profit3.57
Enterprise Value/Ebitda-0.56
Forecast
1Y Price Target
$34.78Price Target Upside240.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
RegenXBio News
See All RGNX News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressRGX-202 improved North Star Ambulatory Assessment (NSAA) and timed function tests, exceeding external natural history control.
Financial StabilityRGNX announced a royalty transaction with Healthcare Royalty, extending cash runway into early-27.
Safety ProfileSafety data is clean with no serious adverse events or adverse events of special interest across 12 dosed patients.
Bears Say
Revenue UncertaintyUncertainty around Zolgensma revenue trajectory and patent duration remains.
Stock PerformanceShares are down over 10% despite functional benefit optically superior to Elevidys, as bears argue small number of patients and optical regression in NSAA make differentiation versus SRPT unclear.
Ownership Overview
8.69% Insiders
13.45% Mutual Funds
21.24% Other Institutional Investors
45.08% Public Companies and Individual Investors
RGNX FAQ
What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was $5.04 and its highest was $15.36 in the past 12 months.
What is RegenXBio’s market cap?
RegenXBio’s market cap is $492.07M.
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s upcoming earnings report date is Jul 30, 2025 which is in 48 days.
How were RegenXBio’s earnings last quarter?
RegenXBio released its earnings results on May 12, 2025. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.46 by -$0.34.
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is -0.94.
How many shares outstanding does RegenXBio have?
RegenXBio has 50,160,350 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
RegenXBio reported an EPS of $0.12 in its last earnings report, missing expectations of $0.46. Following the earnings report the stock price went up 2.635%.
Which hedge fund is a major shareholder of RegenXBio?
Currently, no hedge funds are holding shares in RGNX
RegenXBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.78 (240.98% Upside)
$34.78 (240.98% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 10.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.44%
12-Months-Change
Fundamentals
Return on Equity
-47.44%
Trailing 12-Months
Asset Growth
-21.98%
Trailing 12-Months
Company Description
RegenXBio
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
RGNX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call revealed a strong start to the fiscal year for REGENXBIO, with significant clinical and financial progress. The company's strategic partnerships and manufacturing capabilities position them well for future commercial success, though regulatory uncertainties and competitive pressures remain challenges.Read More>RGNX Stock 12 Month Forecast
Average Price Target
$34.78
▲(240.98%Upside)
Technical Analysis
Inventiva
―
Taysha Gene Therapies
―
Verve Therapeutics
―
Erasca
―
Amylyx Pharmaceuticals Inc
―